Military-Backed Bone Regeneration Tech Completes Major Clinical Milestone

FREDERICK, MD – April 23, 2026 – Theradaptive, Inc., a clinical-stage biotechnology company, announced today it has completed patient enrollment in a pivotal study for a technology that could fundamentally change how surgeons rebuild human bone. The final patient has been treated in the RESTORE international study, a Phase I/II trial evaluating OsteoAdapt® DE, a therapeutic designed to actively regenerate bone for complex dental reconstruction procedures.

The completion of the 45-patient trial marks a significant step forward for the Maryland-based firm and its proprietary protein engineering platform. The study, which compares OsteoAdapt® DE against traditional animal-derived bone grafts, is designed to test a new paradigm in regenerative medicine: actively signaling the body to build new, high-quality bone exactly where it is needed, rather than simply providing a passive scaffold for slow, unpredictable growth.

"Completing enrollment in the RESTORE study is a major achievement that validates the growing clinical interest in our platform," said Dr. Luis Alvarez, Founder and CEO of Theradaptive. "We are grateful to the investigators, clinical teams, patients, and partners whose dedication made this milestone possible. This achievement strengthens our growing body of clinical evidence and brings us closer to delivering meaningful new treatments for patients with limited options."

Beyond the Graft: A New Frontier in Regeneration

For decades, surgeons performing alveolar ridge augmentation—a procedure to rebuild the jawbone before placing dental implants—have relied on a limited toolkit. The options typically include autografts, which involve harvesting bone from another part of the patient's body, or processed grafts from human donors (allografts) and animal sources (xenografts). While autografts are considered the gold standard for their biological properties, they require a second surgical site, increasing pain and recovery time. Xenografts, though widely available, are primarily osteoconductive, meaning they act as a passive framework that the body’s own bone cells must slowly populate. This process can be slow and incomplete.

Theradaptive aims to upend this model with its AMP2™ technology, the engine behind OsteoAdapt® DE. AMP2™ is an engineered variant of human bone morphogenetic protein-2 (BMP-2), a powerful natural signal that instructs stem cells to become bone-forming cells. While BMP-2 has been used in medicine before, its application has been hampered by the need for extremely high doses and its tendency to diffuse away from the target site, leading to potential side effects.

Theradaptive's platform was engineered to solve this problem. It creates material-binding protein variants that can be precisely coated onto an implant or carrier. This allows for a highly localized, sustained release of the therapeutic, enabling active bone formation—or osteoinduction—with greater precision and potentially at lower doses. The goal is to create predictable, robust bone growth that integrates seamlessly with the patient's own tissue, accelerating healing and improving surgical outcomes.

"Participating in the RESTORE study has provided valuable clinical insight into the potential of OsteoAdapt DE as an innovative approach to bone regeneration," stated Dr. Ariel Hirschhorn, a Principal Investigator for the trial at Sheba Medical Center in Israel. "We are encouraged by its potential to address more complex craniomaxillofacial procedures and are proud to contribute to this important advancement in regenerative medicine."

From the Battlefield to the Dentist's Chair

The significance of Theradaptive's technology extends far beyond civilian dental clinics. The RESTORE study is notably supported by a Clinical Trial Award from the U.S. Department of Defense, funneled through the Armed Forces Institute of Regenerative Medicine (AFIRM). This funding underscores the immense military interest in advanced solutions for treating severe trauma.

Service members often suffer from devastating craniofacial and extremity injuries caused by blasts and projectiles, resulting in significant bone loss that is difficult to repair with current methods. AFIRM was established to accelerate the development of regenerative therapies capable of restoring form and function for wounded warriors. Theradaptive's technology, with its potential for robust, targeted bone repair, directly addresses this critical unmet need.

The investment from the Defense Health Agency positions OsteoAdapt® DE as a dual-use technology, with potential applications for both complex military trauma and a wide range of civilian procedures. Success in this field could provide military surgeons with a powerful, off-the-shelf solution to reconstruct shattered jaws, limbs, and skulls, dramatically improving long-term outcomes for injured personnel.

A Platform Poised for Broader Impact

The completion of the RESTORE trial enrollment is not an isolated event for Theradaptive but rather a key validator for its broader therapeutic platform. It marks the second time the company has successfully enrolled a Phase I/II trial, following the completion of its OASIS study. The OASIS trial evaluates a similar product, OsteoAdapt® SP, for use in spinal fusion, another multi-billion-dollar market plagued by inconsistent outcomes.

This dual success across dental and orthopedic applications demonstrates the versatility of the company's underlying technology. With over $50 million raised to date, including a $26 million Series A round in 2023, Theradaptive has been methodically building the clinical evidence and manufacturing capabilities needed to challenge established players. The company has also forged a strategic partnership with ATEC, a major spinal device company, signaling a clear commercialization path for its spinal fusion product.

As an investigational device not yet approved for sale, OsteoAdapt® DE still has a long regulatory road ahead. Following this feasibility study, the company will need to conduct a larger, pivotal trial to definitively prove safety and effectiveness to the FDA, likely through the agency's most stringent Premarket Approval (PMA) pathway for Class III devices. The dental bone graft market, projected to exceed $1.4 billion by 2030, is currently dominated by companies like Geistlich and Straumann, but a truly osteoinductive product could capture significant share by offering superior clinical results.

With enrollment now complete, the medical, military, and investment communities will be closely watching for the initial data from the RESTORE study. According to public trial records, primary results are anticipated by late 2026 or early 2027. These findings will offer the first substantial clinical verdict on OsteoAdapt DE's promise and will shape the next steps on its journey from a groundbreaking concept to a potential new standard of care in reconstructive surgery.